http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#Head http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#assertion http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#provenance http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#pubinfo http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#assertion http://purl.obolibrary.org/obo/DOID_3393 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3393 http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00952 http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association http://www.w3.org/2000/01/rdf-schema#label "Naratriptan tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1) ] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2) ] History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ] Peripheral vascular disease [see Warnings and Precautions (5.5) ] Ischemic bowel disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] Severe renal or hepatic impairment [see Use in Specific Populations (8.6, 8.7), Clinical Pharmacology (12.3)] History of coronary artery disease or coronary artery vasospasm (4) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4) History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4) Peripheral vascular disease (4) Ischemic bowel disease (4) Uncontrolled hypertension (4) Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan) or an ergotamine-containing medication (4) Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) (4) Severe renal or hepatic impairment (4)" http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00952 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#provenance http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#pubinfo http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig http://purl.org/nanopub/x/hasSignature bwa6+y4PCAIPfPKOhAyb7wKM7cxcR9Xjm9OT2Rj5+7nGLjda8LVOqgl5YHrWokVGmeK0vgrsWNYo3R1hVPu50qGi7GMFStP5ttW+ZrirW3/pyQGxD1H8q7t0TPX+Ki9VfrG7a9sDZ79rW5XgARuE4PaSagmd1bTt03qpJMChqP0= http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://purl.org/dc/terms/created 2021-08-23T18:30:22.832+02:00 http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY